title: Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.
abstract: BACKGROUND
  The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNα-RBV).
  
  
  METHODS
  We analyzed the association of the patients' sustained viral responses (SVRs) to PEG-IFNα-RBV therapy with 2 single nucleotide polymorphisms (SNPs) in MRC-1 and 3 SNPs in IL-28B. We selected patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) with or without SVR.
  
  
  RESULTS
  Among the MRC-1 SNPs, rs691005 was found to be associated with SVR in HCV-1-infected patients (P < 0.0001). The IL-28B rs8099917 SNP was found to be associated with SVR in HCV-1- and HCV-2-infected patients (HCV-1, P < 0.0001; HCV-2, P = 0.002), while IL-28B rs955155 and rs10853728 SNPs were found to be associated with SVR in HCV-1-infected patients (P = 0.003) and HCV-2-infected patients (P = 0.02), respectively. We also identified an interaction between MRC-1 rs691005 and IL-28B rs8099917 (P = 0.001). The C-T haplotype was shown to have a positive effect on SVR in HCV-1-infected patients (OR = 1.77, 95% CI = 1.2, 2.62), whereas the T-G haplotype was shown to have a negative effect on SVR in HCV-1-infected patients (OR = 0.28, 95% CI = 0.14, 0.58).
  
  
  CONCLUSIONS
  These results suggest that SNPs of IL-28B and MRC-1 can be used as genetic markers for predicting the outcome of PEG-IFNα-RBV treatment of HCV infections.
authors: Cheng-Yuan
authors: CY
authors: Peng
authors: Ter-Hsin
authors: TH
authors: Chen
authors: Yun-Ping
authors: YP
authors: Lim
authors: School of Chinese Medicine, China Medical University, No, 91, Hsueh-Shih Road, 40402 Taichung, Taiwan. d0704@mail.cmuh.org.tw.
authors: Fuu-Jen
authors: FJ
authors: Tsai
authors: Wei-Yong
authors: WY
authors: Lin
authors: Wen-Ling
authors: WL
authors: Liao
authors: Lei
authors: L
authors: Wan
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics* / Q000276:immunology; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D012367:RNA, Viral / Q000097:blood*; D011971:Receptors, Immunologic / Q000235:genetics* / Q000276:immunology; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D008562:Membrane Glycoproteins; D011092:Polyethylene Glycols; D012367:RNA, Viral; D011971:Receptors, Immunologic; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C573543:MRC1 protein, human